A Prostate Cancer Patients Journey to Another Chance at Life
Can a clinical trial make a difference if you have an advanced form of metastatic prostate cancer? Meet Dr. Judy Wang, the Associate Director of Drug Development for Sarah Cannon Research Institute, a...
Author: patientpower
Added: 07/27/2017 (Source: Oncology Tube)
Source: Oncology Tube - July 28, 2017 Category: Cancer & Oncology Source Type: podcasts
Robert Dreicer, MD, MS, MACP, FASCO - Science and Stories: Making the Most of the Complex Treatment Landscape in Prostate Cancer
Science and Stories: Making the Most of the Complex Treatment Landscape in Prostate Cancer (Source: PeerView CME/CE Audio Podcast - Oncology)
Source: PeerView CME/CE Audio Podcast - Oncology - July 26, 2017 Category: Cancer & Oncology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts
Short Dual-Pulse Sequence versus Standard Multiparametric MR Imaging (September 2017)
ARTICLE DISCUSSED: Detection of Clinically Significant Prostate Cancer: Short Dual-Pulse Sequence versus Standard Multiparametric MR Imaging-A Multireader Study. Radiology 2017;284(3):725-736. (Source: Radiology Podcasts)
Source: Radiology Podcasts - July 24, 2017 Category: Radiology Authors: The Radiological Society of North America Tags: Podcasts Source Type: podcasts
Advanced Prostate Cancer: Advocating for the Best Care
How can prostate cancer patients stay up to date about the latest treatments and advocate for the best care? Andrew Schorr, Patient Power founder, asks this question of an expert panel, including Dr. ...
Author: patientpower
Added: 07/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - July 19, 2017 Category: Cancer & Oncology Source Type: podcasts
PodMed – Week of July 17, 2017
This week’s topics include diet quality and longevity, health and coffee, treating depression, and prostatectomy in early prostate cancer. Program notes: 0:33 Coffee drinking and longevity 1:33 Over 185,000 people followed in one study 2:32 Can’t advocate for a type of coffee 3:01 Prostatectomy or not in early prostate cancer 4:01 Higher incidence of side […] (Source: Johns Hopkins Medicine Weekly Health News)
Source: Johns Hopkins Medicine Weekly Health News - July 14, 2017 Category: Consumer Health News Authors: Elizabeth Tracey Johns Hopkins Medicine Tags: All Podcasts Death and Dying Diet Mental health PodMed Prevention Source Type: podcasts
Robert Dreicer, MD, MS, MACP, FASCO - Urologists at the Intersection of Evidence-Based and Patient-Centric Prostate Cancer Care: Practical Guidance for Everyday Practice
Urologists at the Intersection of Evidence-Based and Patient-Centric Prostate Cancer Care: Practical Guidance for Everyday Practice (Source: PeerView Press CME/CE International Audio Podcast - Internal Medicine)
Source: PeerView Press CME/CE International Audio Podcast - Internal Medicine - July 10, 2017 Category: Internal Medicine Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts
Does Active Surveillance Increase Metastasis Risk for PCa?
Dr Gerald Chodak reviews new data on active surveillance for low-risk prostate cancer and its effect on metastasis-free and prostate cancer-specific survival. (Source: Medscape Medscape Podcast)
Source: Medscape Medscape Podcast - June 29, 2017 Category: General Medicine Authors: Medscape Source Type: podcasts
Trials of acupuncture for stress urinary incontinence and infertility, diabetes epidemiology in China, prostate cancer management, and more
Editor's Audio Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the June 27, 2017 issue (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - June 27, 2017 Category: General Medicine Authors: JAMA, the Journal of the American Medical Association, and The JAMA Network Source Type: podcasts
How do you choose between or identify the right patient for Zytiga or Xtandi?
Nicholas J. Vogelzang, MD of Comprehensive Cancer Centers of Nevada explains how he chooses the right prostate cancer patient for Zytiga (abiraterone acetate) or Xtandi (enzalutamide) at the 2017 ASCO...
Author: obr
Added: 06/23/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 23, 2017 Category: Cancer & Oncology Source Type: podcasts
CHAARTED & amp; STAMPEDE versus LATITUDE in Prostate Cancer
Nicholas J. Vogelzang, MD of Comprehensive Cancer Centers of Nevada discusses the data from the CHAARTED, STAMPEDE, and LATITUDE studies and their impact on treatment of prostate cancer at the 2017 AS...
Author: obr
Added: 06/23/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 23, 2017 Category: Cancer & Oncology Source Type: podcasts
If abiraterone becomes the standard care will there be cost implications_
Nicholas J. Vogelzang, MD of Comprehensive Cancer Centers of Nevada discusses cost implications when abiraterone becomes standard care for prostate cancer treatment. This was recorded at the 2017 ASCO...
Author: obr
Added: 06/23/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 23, 2017 Category: Cancer & Oncology Source Type: podcasts
Should prostate cancer guidelines be updated based on the LATITUDE study?
Daniel Petrylak, MD of Yale School of Medicine discusses whether or not prostate cancer guidelines should be updated based on the new results of the LATITUDE study. This was recorded at the 2017 ASCO ...
Author: obr
Added: 06/22/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2017 Category: Cancer & Oncology Source Type: podcasts
If abiraterone becomes the standard care, will there be cost implications?
Christopher J. Logothetis, MD of MD Anderson Cancer Center discusses the impact of cost with the introduction of abiraterone as standard of care for patients with prostate cancer. This was recorded at...
Author: obr
Added: 06/21/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2017 Category: Cancer & Oncology Source Type: podcasts
